Preclinical evaluation of heat shock protein 90 inhibitor, IPI-504 in human pancreatic xenografts.

被引：0
|
作者：
Song, Dongweon
Jimeno, Antonio
Kulesza, Piotr
Messersmith, Wells
Zhang, Xian Feng
Bouraoud, Nadia
Pien, Christine
Tong, Jeffery
Hidalgo, Manuel
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Infin Pharmaceut Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5475
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
    Wagner, Andrew J.
    Chugh, Rashmi
    Rosen, Lee S.
    Morgan, Jeffrey A.
    George, Suzanne
    Gordon, Michael
    Dunbar, Joi
    Normant, Emmanuel
    Grayzel, David
    Demetri, George D.
    CLINICAL CANCER RESEARCH, 2013, 19 (21) : 6020 - 6029
  • [32] The HSP90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma by downregulation of the prosurvival ER chaperone BiP/Grp78
    Roue, Gael
    Perez-Galan, Patricia
    Lopez-Guerra, Monica
    Villamor, Neus
    Campo, Elias
    Colomer, Dolors
    CANCER RESEARCH, 2009, 69
  • [33] The Hsp90 inhibitor IPI-504 inhibits proliferation and tumor growth of HER2 overexpressing breast cancer cells with acquired trastuzumab resistance
    Scaltriti, Maurizio
    Guzman, Marta
    Normant, Emmanuel
    Jimenez, Jose
    Prudkin, Ludmila
    Aura, Claudia
    Baselga, Jose
    CANCER RESEARCH, 2009, 69
  • [34] Phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with Relapsed/Refractory multiple myeloma (MM).
    Jagannath, S
    Siegel, D
    Richardson, P
    Mazumder, A
    Sydor, J
    Goddard, J
    Walker, J
    Patterson, J
    Normant, E
    Tong, J
    Palombella, V
    Anderson, K
    Adams, J
    Grayzel, D
    BLOOD, 2005, 106 (11) : 719A - 720A
  • [35] The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
    E Normant
    G Paez
    K A West
    A R Lim
    K L Slocum
    C Tunkey
    J McDougall
    A A Wylie
    K Robison
    K Caliri
    V J Palombella
    C C Fritz
    Oncogene, 2011, 30 : 2581 - 2586
  • [36] The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
    Normant, E.
    Paez, G.
    West, K. A.
    Lim, A. R.
    Slocum, K. L.
    Tunkey, C.
    McDougall, J.
    Wylie, A. A.
    Robison, K.
    Caliri, K.
    Palombella, V. J.
    Fritz, C. C.
    ONCOGENE, 2011, 30 (22) : 2581 - 2586
  • [37] Update on phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed/refractory multiple myeloma (MM).
    Siegel, David
    Jagannath, Sundar
    Mazumder, Amitabha
    Vesole, David
    Borrello, Ivan
    Sydor, Jens
    Wright, Jim
    Patterson, Jon
    Normant, Emmanuel
    Adams, Julian
    Anderson, Kenneth
    Grayzel, David
    Richardson, Paul
    BLOOD, 2006, 108 (11) : 1022A - 1022A
  • [38] Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800
    Massey, Andrew J.
    Schoepfer, Joseph
    Brough, Paul A.
    Brueggen, Josef
    Chene, Patrick
    Drysdale, Martin J.
    Pfaar, Ulrike
    Radimerski, Thomas
    Ruetz, Stephan
    Schweitzer, Alain
    Wood, Mike
    Garcia-Echeverria, Carlos
    Jensen, Michael Rugaard
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (04) : 906 - 919
  • [39] Preclinical activity of the heat shock protein 90 inhibitor ganetespib in clear cell renal cell carcinoma.
    Parasramka, Mansi
    Proia, David A.
    Joseph, Richard Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor
    Vesci, Loredana
    Milazzo, Ferdinando Maria
    Carollo, Valeria
    Pace, Silvia
    Giannini, Giuseppe
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (04) : 1421 - 1429
12345